Drug Profile
Hydrogen peroxide topical - Aclaris Therapeutics
Alternative Names: A-101 - Aclaris; A-101 45%; ESKATA; ESKERIELE; HP-40; HP-45; Oxydol; V-101 - AclarisLatest Information Update: 22 Mar 2022
Price :
$50
*
At a glance
- Originator Aclaris Therapeutics
- Developer Aclaris Therapeutics; Cipher Pharmaceuticals
- Class Antibacterials; Antiseptics; Disinfectants; Peroxides; Skin disorder therapies
- Mechanism of Action Antioxidants; Free radical stimulants; Oxidoreductase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Seborrhoeic keratosis; Warts
Highest Development Phases
- Phase III Warts
- No development reported Seborrhoeic keratosis
Most Recent Events
- 22 Mar 2022 No development reported - Preregistration for Seborrhoeic keratosis in Canada, Norway, Spain, Austria, France, Germany, Netherlands, Ireland, Italy, Portugal, Czech Republic (Topical)
- 07 May 2020 Aclaris Therapeutics plans to launch hydrogen peroxide (45%) for Warts and hydrogen peroxide (40%) (Topical)
- 20 Dec 2019 Aclaris Therapeutics completes a phase III trial in Warts in USA (NCT03812510)